{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:36:22Z","timestamp":1776699382816,"version":"3.51.2"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14960-w","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:40:10Z","timestamp":1759246810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Nizar","family":"Abu Hamdeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Alnees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Ewidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraheem","family":"AbuAlrub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duha","family":"Najajra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalaziz","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari","family":"Zraiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basem","family":"Bali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Hadya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Khaleel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faridah","family":"Ihmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khairi","family":"Alzirei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qasem","family":"Salah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Yaghmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Marrawani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malak M.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eithar","family":"AbuAlsuod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loay","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Allaham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuha","family":"Riyad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amid","family":"Barq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abed","family":"Alawna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza A.","family":"Abdul-Hafez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Masu\u2019d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oswatalrasoul Anan Abdulaziz","family":"Dweikat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitham","family":"Abu Khadija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"8","key":"14960_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"1","key":"14960_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.33696\/haematology.4.055","volume":"4","author":"MJ Nieto","year":"2023","unstructured":"Nieto MJ, Hedjar A, Locke M, Caro J, Saif MW. Analysis of updates in multiple myeloma treatment and management. J Clin Haematol. 2023;4(1):35\u201342.","journal-title":"J Clin Haematol"},{"key":"14960_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajem.2024.11.073","volume":"88","author":"B Long","year":"2025","unstructured":"Long B, McCurdy A, Koyfman A, Rosenberg H. An emergency medicine review: multiple myeloma and its complications. Am J Emerg Med. 2025;88:172\u20139.","journal-title":"Am J Emerg Med"},{"issue":"9","key":"14960_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"2","key":"14960_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2023.103920","volume":"31","author":"MS Abduh","year":"2024","unstructured":"Abduh MS. An overview of multiple myeloma: a monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities. Saudi J Biol Sci. 2024;31(2):103920.","journal-title":"Saudi J Biol Sci"},{"key":"14960_CR6","unstructured":"American Cancer Society. Cancer Statistics at a Glance: Top 5 Most Common Cancers, 2022. Atlanta (GA): American Cancer Society; 2022. Available from: https:\/\/cancerstatisticscenter.cancer.org\/"},{"issue":"5","key":"14960_CR7","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/10428194.2018.1523399","volume":"60","author":"J Tay","year":"2019","unstructured":"Tay J, Vij R, Norkin M, Buadi F, Kindwall-Keller TL, Roberts JS, et al. Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. Leuk Lymphoma. 2019;60(5):1275\u201382.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"14960_CR8","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/cncr.34133","volume":"128","author":"RM Williams","year":"2022","unstructured":"Williams RM, Cordon M, Eyestone E, Smith L, Luta G, McKee BJ, et al. Improved motivation and readiness to quit shortly after lung cancer screening: evidence for a teachable moment. Cancer. 2022;128(10):1976\u201386. https:\/\/doi.org\/10.1002\/cncr.34133.","journal-title":"Cancer"},{"issue":"2","key":"14960_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40.","journal-title":"Blood Cancer J"},{"issue":"6","key":"14960_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.25764","volume":"95","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: implications for survivorship. Am J Hematol. 2020;95(6):672\u201390.","journal-title":"Am J Hematol"},{"issue":"2\u20133","key":"14960_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/10376178.2019.1623699","volume":"55","author":"HY Kang","year":"2019","unstructured":"Kang HY, Choi EY. Factors influencing quality of life in patients with multiple myeloma. Contemp Nurse. 2019;55(2\u20133):109\u201321.","journal-title":"Contemp Nurse"},{"key":"14960_CR12","doi-asserted-by":"crossref","unstructured":"Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Supportive Care in Cancer [Internet]. 2015[cited 2025 Jun 3];23(5):1431\u201345. Available from:\u00a0https:\/\/link.springer.com\/article\/10.1007\/s00520-014-2552-1.","DOI":"10.1007\/s00520-014-2552-1"},{"issue":"6","key":"14960_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015;100(6):826\u201333.","journal-title":"Haematologica"},{"issue":"2","key":"14960_CR14","first-page":"417","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a european, multicenter cohort study. Support Care Cancer. 2014;22(2):417\u201326.","journal-title":"Support Care Cancer"},{"issue":"1","key":"14960_CR15","first-page":"e20230100","volume":"77","author":"LA Lorca","year":"2024","unstructured":"Lorca LA, Sacomori C, Pe\u00f1a C, Barrera C, Salazar M, Le\u00e3o I, et al. Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma. Rev Bras Enferm. 2024;77(1):e20230100.","journal-title":"Rev Bras Enferm"},{"key":"14960_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1429","author":"H Ludwig","year":"2022","unstructured":"Ludwig H, Bailey AL, Marongiu A, Khela K, Milligan G, Carlson KB, et al. Patient-reported pain severity and health\u2010related quality of life in patients with multiple myeloma in real world clinical practice. Cancer Rep. 2022. https:\/\/doi.org\/10.1002\/cnr2.1429.","journal-title":"Cancer Rep"},{"issue":"11","key":"14960_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/10428194.2023.2240922","volume":"64","author":"LR Dachs","year":"2023","unstructured":"Dachs LR, Gais\u00e1n CM, Bustamante G, L\u00f3pez SG, Garc\u00eda EG, Persona EP, et al. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of life outcomes in patients with relapsed and\/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study. Leuk Lymphoma. 2023;64(11):1847\u201356. https:\/\/doi.org\/10.1080\/10428194.2023.2240922.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"14960_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2217\/pmt-2021-0013","volume":"12","author":"B Quinn","year":"2022","unstructured":"Quinn B, Ludwig H, Bailey A, Khela K, Marongiu A, Carlson KB, et al. Physical, emotional and social pain communication by patients diagnosed and living with multiple myeloma. Pain Manag. 2022;12(1):59\u201374. https:\/\/doi.org\/10.2217\/pmt-2021-0013.","journal-title":"Pain Manag"},{"issue":"12","key":"14960_CR19","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"1","key":"14960_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-35","volume":"12","author":"I Proskorovsky","year":"2014","unstructured":"Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12(1):35.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"14960_CR21","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s11136-012-0261-0","volume":"22","author":"HAS Huijer","year":"2013","unstructured":"Huijer HAS, Sagherian K, Tamim H. Validation of the Arabic version of the EORTC quality of life questionnaire among cancer patients in Lebanon. Qual Life Res. 2013;22(6):1473\u201381.","journal-title":"Qual Life Res"},{"issue":"21","key":"14960_CR22","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1182\/blood.V124.21.2605.2605","volume":"124","author":"S Paul","year":"2014","unstructured":"Paul S, Kochuparambil ST, Thompson CA, Shanafelt TD, Buadi FK, Lacy MQ, et al. Quality of life and outcomes in multiple myeloma patients. Blood. 2014;124(21):2605\u20132605. https:\/\/doi.org\/10.1182\/blood.V124.21.2605.2605.","journal-title":"Blood"},{"key":"14960_CR23","doi-asserted-by":"publisher","unstructured":"Aaronson NK, et al. The EORTC QLQ-MY20: a modular supplement to the EORTC QLQ-C30 for use in assessing quality of life in patients with multiple myeloma. Eur J Cancer. 1999;35(5):635\u201342. https:\/\/doi.org\/10.1016\/S0959-8049(98)00415-9.","DOI":"10.1016\/S0959-8049(98)00415-9"},{"key":"14960_CR24","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician [Internet]. 2017[cited 2025 Aug 16];95(6):373-383A. Available from: https:\/\/www.aafp.org\/pubs\/afp\/issues\/2017\/0315\/p373.html."},{"key":"14960_CR25","unstructured":"the National Cancer Institute. NCI Comorbidity Index Overview [Internet]. Bethesda (MD): National Cancer Institute;[cited 2025 Sep 4]. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html"},{"key":"14960_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00815-9","author":"KA Forde","year":"2023","unstructured":"Forde KA, Cocks K, Wells JR, McMillan I, Kyriakou C. Use of the European organisation for research and treatment of cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development. Blood Cancer J. 2023. https:\/\/doi.org\/10.1038\/s41408-023-00815-9.","journal-title":"Blood Cancer J"},{"key":"14960_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08453-9","author":"G Tremblay","year":"2021","unstructured":"Tremblay G, Daniele P, Breeze JL, Li L, Shah JJ, Shacham S, et al. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) treatment of refractory myeloma (STORM) phase 2b study. BMC Cancer. 2021. https:\/\/doi.org\/10.1186\/s12885-021-08453-9.","journal-title":"BMC Cancer"},{"issue":"18","key":"14960_CR28","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1097\/CM9.0000000000002017","volume":"135","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zheng H, Wang F, Zhang L, Zhang Y, Liu X, et al. Percutaneous vertebroplasty combined with chemotherapy in the treatment of multiple myeloma patients with vertebral compression fractures. Chin Med J (Engl). 2022;135(18):2242\u20134.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"14960_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40271-021-00501-7","volume":"14","author":"J He","year":"2021","unstructured":"He J, Duenas A, Collacott H, Lam A, Gries KS, Carson R, et al. Patient perceptions regarding multiple myeloma and its treatment: qualitative evidence from interviews with patients in the United Kingdom, France, and Germany. The Patient. 2021;14(5):613\u201323.","journal-title":"The Patient"},{"issue":"6","key":"14960_CR30","first-page":"4961","volume":"30","author":"F Chen","year":"2022","unstructured":"Chen F, Leng Y, Ni J, Niu T, Zhang L, Li J, et al. Symptom clusters and quality of life in ambulatory patients with multiple myeloma. Support Care Cancer. 2022;30(6):4961\u201370.","journal-title":"Support Care Cancer"},{"key":"14960_CR31","doi-asserted-by":"publisher","unstructured":"Ludwig H, Moreau P, Dimopoulos M \u0391, Mateos M, Kaiser M, H\u00e1jek R, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma. Blood Cancer J. 2019. https:\/\/doi.org\/10.1038\/s41408-019-0181-0.","DOI":"10.1038\/s41408-019-0181-0"},{"key":"14960_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10101-9","author":"J Fischer","year":"2022","unstructured":"Fischer J, Knop S, Danhof S, Einsele H, Keller D, L\u00f6ffler C. The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study. BMC Cancer. 2022. https:\/\/doi.org\/10.1186\/s12885-022-10101-9.","journal-title":"BMC Cancer"},{"issue":"7","key":"14960_CR33","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ajh.27326","volume":"99","author":"R Silbermann","year":"2024","unstructured":"Silbermann R, Laubach JP, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, et al. Health-related quality of life in Transplant\u2010eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient\u2010reported outcomes from griffin. Am J Hematol. 2024;99(7):1257\u201368.","journal-title":"Am J Hematol"},{"issue":"1","key":"14960_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bjh.17435","volume":"194","author":"T Plesner","year":"2021","unstructured":"Plesner T, Dimopoulos M\u0391, Oriol A, Miguel JFS, Bahlis NJ, Rabin N, et al. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. Br J Haematol. 2021;194(1):132\u20139.","journal-title":"Br J Haematol"},{"key":"14960_CR35","doi-asserted-by":"publisher","unstructured":"Schjesvold F, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, et al. Health-Related Quality of Life in Relapsed\/Refractory Multiple Myeloma Treated With Melflufen and Dexamethasone: Analyses From the Phase III OCEAN Study. Haematologica. 2024;109(1):40\u201352. https:\/\/doi.org\/10.3324\/haematol.2023.283557.","DOI":"10.3324\/haematol.2023.283557"},{"key":"14960_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07902-4","author":"T Wang","year":"2023","unstructured":"Wang T, Lu Q, Tang L. Assessment tools for patient-reported outcomes in multiple myeloma. Support Care Cancer. 2023. https:\/\/doi.org\/10.1007\/s00520-023-07902-4.","journal-title":"Support Care Cancer"},{"key":"14960_CR37","doi-asserted-by":"publisher","unstructured":"Dombeck CB, Swezey T, Gonz\u00e1lez JM, Reeve BB, LeBlanc TW, Chandler D, et al. Patient Perspectives on Considerations, Tradeoffs, and Experiences With Multiple Myeloma Treatment Selection: A Qualitative Descriptive Study. BMC Cancer. 2023;23(1):867. https:\/\/doi.org\/10.1186\/s12885-023-11368-2.","DOI":"10.1186\/s12885-023-11368-2"},{"key":"14960_CR38","doi-asserted-by":"publisher","DOI":"10.2174\/18744346-v17-e230111-2022-127","author":"C Posada","year":"2023","unstructured":"Posada C, Correa L, Casta\u00f1eda M, Arias-Rojas M, Tellez B. Relationship between adoption of the caregiver role and quality of life in caregivers of cancer patients under active treatment. Open Nurs J. 2023. https:\/\/doi.org\/10.2174\/18744346-v17-e230111-2022-127.","journal-title":"Open Nurs J"},{"issue":"19\u201320","key":"14960_CR39","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1111\/jocn.16791","volume":"32","author":"L Zeng","year":"2023","unstructured":"Zeng L, Huang H, Chen Q, Ruan C, Liu Y, An W, et al. Multiple myeloma patients undergoing chemotherapy: which symptom clusters impact quality of life?? J Clin Nurs. 2023;32(19\u201320):7247\u201359.","journal-title":"J Clin Nurs"},{"issue":"4","key":"14960_CR40","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","volume":"6","author":"M Delforge","year":"2022","unstructured":"Delforge M, Shah N, Miguel JFS, Braverman J, Dhanda D, Shi L, et al. Health-Related quality of life with Idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309\u201318.","journal-title":"Blood Adv"},{"issue":"2","key":"14960_CR41","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M, Rieth A, Saba G, Pellan M, et al. Real-World evaluation of Health-Related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21(2):e160\u201375.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"14960_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194711","volume":"15","author":"LB Oswald","year":"2023","unstructured":"Oswald LB, Gudenkauf LM, Li X, Avila GD, Peres LC, Kirtane K, et al. Patient-reported outcomes among multiple myeloma patients treated with standard of care Idecabtagene vicleucel. Cancers (Basel). 2023;15(19):4711.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"14960_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-024-03943-1","volume":"24","author":"R Olofsson","year":"2024","unstructured":"Olofsson R, Korytowska M, Almh\u00f6jd U, Almst\u00e5hl A, \u00c7evik-Aras H. Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma \u2013 a longitudinal cohort study. BMC Oral Health. 2024;24(1):184.","journal-title":"BMC Oral Health"},{"key":"14960_CR44","doi-asserted-by":"publisher","unstructured":"Almuhaysen LM, Alaa ABA. A Study on Renal Failure Management in Patients Diagnosed With Multiple Myeloma. Cureus. 2023;15(6):e39862. https:\/\/doi.org\/10.7759\/cureus.39862.","DOI":"10.7759\/cureus.39862"},{"issue":"23","key":"14960_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14236007","volume":"14","author":"S Salek","year":"2022","unstructured":"Salek S, Ionova T, Ol\u00edva EN, Andreas M, Skoetz N, Kreuzberger N, et al. The reporting, use, and validity of Patient-Reported outcomes in multiple myeloma in clinical trials: a systematic literature review. Cancers (Basel). 2022;14(23):6007.","journal-title":"Cancers (Basel)"},{"key":"14960_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01830-4","author":"G Joshy","year":"2020","unstructured":"Joshy G, Thandrayen J, Koczwara B, Butow P, Laidsaar-Powell R, Rankin N, et al. Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer. BMC Med. 2020. https:\/\/doi.org\/10.1186\/s12916-020-01830-4.","journal-title":"BMC Med"},{"key":"14960_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","volume":"107","author":"S Nolte","year":"2019","unstructured":"Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers P, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the unites States. Eur J Cancer. 2019;107:153\u201363.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14960-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14960-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14960-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:40:15Z","timestamp":1759246815000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14960-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14960"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14960-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Najah National University in Palestine. Written informed consent was obtained from all participants before data collection. The study was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not include any individual personal data in any form (e.g., images, videos, personal details).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1472"}}